
RPRX Valuation
Royalty Pharma PLC
$
31.950
- Overview
- Forecast
- Valuation
RPRX Relative Valuation
RPRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RPRX is overvalued; if below, it's undervalued.
Historical Valuation
Royalty Pharma PLC (RPRX) is now in the Undervalued zone, suggesting that its current forward PE ratio of 6.56 is considered Undervalued compared with the five-year average of 10.91. The fair price of Royalty Pharma PLC (RPRX) is between 36.75 to 65.21 according to relative valuation methord. Compared to the current price of 31.95 USD , Royalty Pharma PLC is Undervalued By 13.05%.
Relative Value
Fair Zone
36.75-65.21
Current Price:31.95
13.05%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
1.97
P/B
Median3y
2.36
Median5y
2.70
19.80
FCF Yield
Median3y
18.10
Median5y
15.83
Competitors Valuation Multiple
The average P/S ratio for RPRX's competitors is 6.93, providing a benchmark for relative valuation. Royalty Pharma PLC Corp (RPRX) exhibits a P/S ratio of 4.75, which is -31.48% above the industry average. Given its robust revenue growth of -0.41%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
Revenue Growth
Market Cap

RPRX.O
Royalty Pharma PLC
4.75
Average P/S: 6.93
-0.41%
18.40B

HASI.N
Hannon Armstrong Sustainable Infrastructure Capital Inc
16.52
16.99%
2.78B

Loss
0.00

IGIC.O
International General Insurance Holdings Ltd
Loss
5.37%
1.08B

BCSF.N
Bain Capital Specialty Finance Inc
3.30
-13.02%
919.47M

TRIN.O
Trinity Capital Inc
3.15
102.88%
851.05M
People Also Watch

NESR
National Energy Services Reunited Corp
5.960
USD
-1.32%

BFS
Saul Centers Inc
32.850
USD
+1.64%

ABCL
Abcellera Biologics Inc
2.400
USD
+15.94%

GDEN
Golden Entertainment Inc
25.120
USD
-1.49%

GRNT
Granite Ridge Resources Inc
4.890
USD
+2.95%

AVAH
Aveanna Healthcare Holdings Inc
4.490
USD
-6.46%

MRNO
Murano Global Investments Plc
9.080
USD
-4.42%

COGT
Cogent Biosciences Inc
4.260
USD
+5.97%

HTLD
Heartland Express Inc
8.450
USD
-2.09%

REAX
Real Brokerage Inc
4.315
USD
+1.05%
FAQ

Is Royalty Pharma PLC (RPRX) currently overvalued or undervalued?
Royalty Pharma PLC (RPRX) is now in the Undervalued zone, suggesting that its current forward PE ratio of 6.56 is considered Undervalued compared with the five-year average of 10.91. The fair price of Royalty Pharma PLC (RPRX) is between 36.75 to 65.21 according to relative valuation methord. Compared to the current price of 31.95 USD , Royalty Pharma PLC is Undervalued By 13.05%.

What is Royalty Pharma PLC (RPRX) fair value?

How does RPRX's valuation metrics compare to the industry average?

What is the current P/B ratio for Royalty Pharma PLC (RPRX) as of Apr 11 2025?

What is the current FCF Yield for Royalty Pharma PLC (RPRX) as of Apr 11 2025?

What is the current Forward P/E ratio for Royalty Pharma PLC (RPRX) as of Apr 11 2025?
